99mTc-TRODAT-1 imaging of multiple system atrophy

Area of Science:

• Neuroimaging
• Nuclear Medicine
• Neurology

Background:

• Multiple System Atrophy (MSA) presents with parkinsonian (MSA-P) and cerebellar (MSA-C) features, often overlapping with Parkinson's Disease (PD).
• Accurate differentiation is crucial for prognosis and management.
• Dopamine transporter (DAT) imaging is a key tool in evaluating parkinsonian syndromes.

Purpose of the Study:

• To assess the utility of (99m)Tc-TRODAT-1 brain SPECT in differentiating MSA subtypes (MSA-P and MSA-C) from each other and from PD.
• To correlate DAT imaging findings with clinical presentation and disease severity.

Main Methods:

• SPECT imaging using (99m)Tc-TRODAT-1 was performed on 49 MSA patients (30 MSA-P, 19 MSA-C), 36 PD patients, and 33 healthy controls.
• Quantification of striatal binding ratios (S/O, P/O, C/O, P/C) and striatal binding symmetry was analyzed.
• Statistical analyses included ANOVA and Spearman correlation with UPDRS-III scores.

Main Results:

• Striatal binding was reduced in all patient groups compared to controls.
• MSA-P showed more symmetric nigrostriatal damage (asymmetric index 14.2) than PD (28.6), while MSA-C had less symmetric reduction (8.1).
• (99m)Tc-TRODAT-1 binding correlated with UPDRS-III scores in PD but not in MSA subtypes.

Conclusions:

• (99m)Tc-TRODAT-1 SPECT can differentiate between MSA-P and MSA-C subtypes based on the pattern and symmetry of nigrostriatal damage.
• This imaging modality likely provides valuable information for differentiating MSA from PD.
• The distinct patterns of DAT reduction support the use of SPECT in the etiological diagnosis of parkinsonian syndromes.